Skip to main content

Table 2 Comparison of baseline metabolic profile between P/I ratio responders and non-responders

From: The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study

  Responder Non responder
n (M/F) 8 (5/3) 7 (5/2)
BMI, kg/m2 23.6 ± 4.2 26.4 ± 4.1
HbA1c(NGSP),% 6.8 ± 0.4 6.9 ± 0.7
HOMA-R 1.85 ± 1.18 3.90 ± 4.58
ISI (Matsuda’s index) 9.30 ± 2.35 6.15 ± 3.23*
Insulinogenic index 1.01 ± 0.69 0.43 ± 0.30*
PI/I ratio 0.08 ± 0.06 0.13 ± 0.15
CPR, nmol/L 0.66 ± 0.33 0.66 ± 0.33
(ng/dL) (2.0 ± 1.0) (2.0 ± 1.0)
Total cholesterol, mmol/L 5.18 ± 1.21 5.54 ± 0.59
(mg/dL) (200 ± 47) (214 ± 23)
Triglyceride, mmol/L 1.19 ± 0.50 2.32 ± 1.40*
(mg/dL) (106 ± 45) (206 ± 124*)
HDL-C, mmol/L 1.73 ± 0.51 1.16 ± 0.31*
(mg/dL) (67 ± 20) (45 ± 12*)
  1. Mean ± SD *P < 0.05 vs responder (paired t-test).
  2. BMI, body mass index; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; PI/I ratio, proinsulin/insulin ratio; CPR, C-peptide immunoreactivity; HDL-C, high-density lipoprotein cholesterol; IRI, immunoreactive insulin.